ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.593,14
-0,49%
S&P 500
5.306,04
0,02%
Dow Jones
38.852,86
-0,55%
Euro vs US Dollar
1,0832
-0,20%
Bitcoin
67.727,06
-0,83%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. NewAmsterdam Pharma Company NV (NAMSW)

  7. NewAmsterdam Pharma Company NV (NAMSW) News

NAMSW

NewAmsterdam Pharma Comp... (NAMSW)

NewAmsterdam Pharma Company NV
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:NAMSW
DatumZeitQuelleÜberschriftSymbolFirma
21/05/202414h00GlobeNewswire Inc.NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical MeetingsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
09/05/202422h18Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:NAMSWNewAmsterdam Pharma Company NV
09/05/202422h15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
09/05/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
09/05/202414h00GlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial ResultsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
08/05/202422h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NAMSWNewAmsterdam Pharma Company NV
03/05/202422h01GlobeNewswire Inc.NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NAMSWNewAmsterdam Pharma Company NV
02/05/202414h00GlobeNewswire Inc.NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024NASDAQ:NAMSWNewAmsterdam Pharma Company NV
09/04/202414h00GlobeNewswire Inc.NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular DiseaseNASDAQ:NAMSWNewAmsterdam Pharma Company NV
01/04/202414h00GlobeNewswire Inc.NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business OfficerNASDAQ:NAMSWNewAmsterdam Pharma Company NV
25/03/202413h00GlobeNewswire Inc.NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology CongressNASDAQ:NAMSWNewAmsterdam Pharma Company NV
12/03/202413h00GlobeNewswire Inc.NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVDNASDAQ:NAMSWNewAmsterdam Pharma Company NV
28/02/202414h00GlobeNewswire Inc.NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:NAMSWNewAmsterdam Pharma Company NV
26/02/202414h00GlobeNewswire Inc.NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in MarchNASDAQ:NAMSWNewAmsterdam Pharma Company NV
14/02/202404h40GlobeNewswire Inc.NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
13/02/202422h01GlobeNewswire Inc.NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
01/02/202422h01GlobeNewswire Inc.NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:NAMSWNewAmsterdam Pharma Company NV
08/01/202414h00GlobeNewswire Inc.NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of DirectorsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
04/01/202414h00GlobeNewswire Inc.NewAmsterdam Pharma Announces 2024 Strategic PrioritiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
13/11/202314h00GlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial HighlightsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
23/10/202314h00GlobeNewswire Inc.NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial OfficerNASDAQ:NAMSWNewAmsterdam Pharma Company NV
21/09/202313h00GlobeNewswire Inc.NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 MutationNASDAQ:NAMSWNewAmsterdam Pharma Company NV
20/09/202314h00GlobeNewswire Inc.NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:NAMSWNewAmsterdam Pharma Company NV
14/08/202322h01GlobeNewswire Inc.NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial OfficerNASDAQ:NAMSWNewAmsterdam Pharma Company NV
07/08/202313h15GlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial HighlightsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
25/07/202322h01GlobeNewswire Inc.NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular DiseaseNASDAQ:NAMSWNewAmsterdam Pharma Company NV
09/06/202322h01GlobeNewswire Inc.NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary SharesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
07/06/202305h25GlobeNewswire Inc.NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary SharesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
06/06/202322h01GlobeNewswire Inc.NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary SharesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
05/06/202313h00GlobeNewswire Inc.NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese PatientsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
 Showing the most relevant articles for your search:NASDAQ:NAMSW

Kürzlich von Ihnen besucht

DBI
D1AB
DAXplus Seasonal Strateg...
NASDAQ
ECLG
Ecollege
COIN
HOLLYEUR
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten